Article
Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
Trials - 12 May 2011
Tanaka Shiro, Sakamori Yuichi, Niimi Miyuki, Hazama Megumi, Kim Young H, Yanagihara Kazuhiro
Abstract excerpt
BACKGROUND: Combination of erlotinib and bevacizumab is a promising regimen in advanced non-squamous non-small-cell lung cancer (NSCLC). We are conducting a single arm phase II trial which aims to evaluate the efficacy and safety of this regime as a second- or third-line chemotherapy. METHODS: Key eligibility criteria were histologically or cytologically confirmed non-squamous NSCLC, stage III/IV or recurrent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.